Show simple item record

dc.contributor.authorCapasso, Cristian
dc.contributor.authorHirvinen, Mari
dc.contributor.authorGarofalo, Mariangela
dc.contributor.authorRomaniuk, Dmitrii
dc.contributor.authorKuryk, Lukasz
dc.contributor.authorSarvela, Teea
dc.contributor.authorVitale, Andrea
dc.contributor.authorAntopolsky, Maxim
dc.contributor.authorMagarkar, Aniket
dc.contributor.authorViitala, Tapani
dc.contributor.authorSuutari, Teemu
dc.contributor.authorBunker, Alex
dc.contributor.authorYliperttula, Marjo
dc.contributor.authorUrtti, Arto
dc.contributor.authorCerullo, Vincenzo
dc.date.accessioned2016-10-04T11:12:35Z
dc.date.available2016-10-04T11:12:35Z
dc.date.issued2016
dc.identifierhttp://doi.org/10.1080/2162402X.2015.1105429fi_FI
dc.identifier.citationCristian Capasso, Mari Hirvinen, Mariangela Garofalo, Dmitrii Romaniuk, Lukasz Kuryk, Teea Sarvela, Andrea Vitale, Maxim Antopolsky, Aniket Magarkar, Tapani Viitala, Teemu Suutari, Alex Bunker, Marjo Yliperttula, Arto Urtti & Vincenzo Cerullo (2016) Oncolytic adenoviruses coated with MHC-I tumor epitopes increase the antitumor immunity and efficacy against melanoma, OncoImmunology, 5:4, e1105429, DOI: 10.1080/2162402X.2015.1105429fi_FI
dc.identifier.issn2162-402X
dc.identifier.urihttps://erepo.uef.fi/handle/123456789/141
dc.descriptionArticle
dc.description.abstractThe stimulation of the immune system using oncolytic adenoviruses (OAds) has attracted significant interest and several studies suggested that OAds immunogenicity might be important for their efficacy. Therefore, we developed a versatile and rapid system to adsorb tumor-specific major histocompatibility complex class I (MHC-I) peptides onto the viral surface to drive the immune response toward the tumor epitopes. By studying the model epitope SIINFEKL, we demonstrated that the peptide-coated OAd (PeptiCRAd) retains its infectivity and the cross presentation of the modified-exogenous epitope on MHC-I is not hindered. We then showed that the SIINFEKL-targeting PeptiCRAd achieves a superior antitumor efficacy and increases the percentage of antitumor CD8+ T cells and mature epitope-specific dendritic cells in vivo. PeptiCRAds loaded with clinically relevant tumor epitopes derived from tyrosinase-related protein 2 (TRP-2) and human gp100 could reduce the growth of primary-treated tumors and secondary-untreated melanomas, promoting the expansion of antigen-specific T-cell populations. Finally, we tested PeptiCRAd in humanized mice bearing human melanomas. In this model, a PeptiCRAd targeting the human melanoma-associated antigen A1 (MAGE-A1) and expressing granulocyte and macrophage colony-stimulating factor (GM-CSF) was able to eradicate established tumors and increased the human MAGE-A1-specific CD8+ T cell population. Herein, we show that the immunogenicity of OAds plays a key role in their efficacy and it can be exploited to direct the immune response system toward exogenous tumor epitopes. This versatile and rapid system overcomes the immunodominance of the virus and elicits a tumor-specific immune response, making PeptiCRAd a promising approach for clinical testing.fi_FI
dc.language.isoenfi_FI
dc.publisherLandes Bioscience; European Academy of Tumor Immunologyfi_FI
dc.relation.ispartofseriesOncoimmunology
dc.relation.urihttp://doi.org/10.1080/2162402X.2015.1105429fi_FI
dc.rightsCC BY https://creativecommons.org/licenses/by-nc/3.0/fi_FI
dc.subjecthumanized micefi_FI
dc.subjectimmunotherapyfi_FI
dc.subjectmelanomafi_FI
dc.subjectoncolytic adenovirusfi_FI
dc.subjectoncolytic vaccinefi_FI
dc.subjecttumor epitopesfi_FI
dc.subjectcancer vaccinefi_FI
dc.titleOncolytic adenoviruses coated with MHC-I tumor epitopes increase the antitumor immunity and efficacy against melanomafi_FI
dc.typehttp://purl.org/eprint/type/JournalArticle
dc.description.versionPublisher's pdffi_FI
dc.contributor.departmentFaculty of Health Sciences
dc.contributor.departmentSchool of Pharmacy, Activities
uef.solecris.id40173810
eprint.statushttp://purl.org/eprint/status/PeerReviewedfi_FI
dc.type.publicationinfo:eu-repo/semantics/article
dc.rights.accessrights© Authors
dc.relation.doi10.1080/2162402X.2015.1105429
dc.description.reviewstatushttp://purl.org/eprint/status/PeerReviewed
dc.relation.articlenumbere1105429
dc.relation.issn2162-402X
dc.relation.issue4
dc.relation.volume5


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record